CV SCIENCES INC - CVSI STOCK NEWS

Welcome to our dedicated page for CV SCIENCES news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on CV SCIENCES stock.

CV Sciences, Inc. (CVSI) is a consumer wellness company dedicated to improving health through the integration of science and nature. Specializing in hemp extracts and science-backed natural ingredients, CV Sciences offers a range of products such as hemp extracts, softgels, and plant-based foods. The company's commitment to consumer well-being is evident in its mission to make healthy people healthier. With a focus on research-supported, plant-based alternatives, CV Sciences aims to provide high-quality products that cater to the well-being of both humans and pets. The recent launch of +PlusCBD™ Pet wellness treats, including the Pet Hip and Joint Health Chews and Pet Calming Care Chews, showcases CV Sciences' dedication to innovation and safety, validated by the National Animal Supplement Council (NASC). These premium CBD-infused chews, designed to support pet health, are crafted using organic hemp-derived CBD and a blend of antioxidants, anti-inflammatory agents, and essential supplements. The safety, efficacy, and quality of each product are ensured through rigorous testing by independent laboratories, aligning with NASC's stringent standards.

CV Sciences' strategic acquisitions, such as Elevated Softgels, further enhance its operational capabilities, allowing for in-house manufacturing and new product development. By leveraging Elevated Softgels' manufacturing expertise, CV Sciences aims to streamline production, increase operational efficiency, and expand its product offerings. The company's financial performance reflects its resilience and growth trajectory, with sequential revenue increases, improved gross margins, and strategic investments driving long-term value creation. As CV Sciences continues to innovate and expand its product portfolio, it remains committed to delivering science-backed, plant-based solutions that promote holistic well-being.

03/26/2024 08:00 AM

News

CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews

Rhea-AI Summary

CV Sciences, Inc. launches +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews, backed by a safety study from the National Animal Supplement Council. The chews aim to improve pets' physical and emotional well-being with CBD and other natural ingredients, addressing joint pain and anxiety. The products are available nationwide and uphold strict quality standards, offering pet owners a safe and effective alternative.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/21/2024 09:00 AM

News

CV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2023 RESULTS ON MARCH 28, 2024

Rhea-AI Summary

CV Sciences, Inc. (CVSI) will release financial results for the year and fourth quarter ended December 31, 2023, on March 28, 2024. The Company will hold a conference call with investors on the same day.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-25%

Tags

12/12/2023 08:00 AM

News

CV Sciences, Inc. Acquires Cultured Foods To Enter Plant-Based Food Market, Opening Door For European Distribution

Rhea-AI Summary

CV Sciences, Inc. (OTCQB: CVSI) has completed the acquisition of Cultured Foods, a leading manufacturer and distributor of alternative plant-based vegan foods, for a total consideration of up to $535,000. The acquisition creates opportunities for importation of specialty foods to the US and establishes a European base of operations for the sale and distribution of +PlusCBD products, contributing to the transition of CV Sciences into a more diverse global health and wellness company.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/14/2023 09:00 AM

News

CV Sciences, Inc. Reports Third Quarter 2023 Financial Results

Rhea-AI Summary

CV Sciences, Inc. (OTCQB:CVSI) announced its financial results for the quarter ended September 30, 2023, with increased revenue to $4.1 million, recognized gross margin of 45.1%, and a cash balance of $1.6 million. The company also launched new products, executed an M&A strategy, and evaluated partnership opportunities.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/09/2023 09:00 AM

News

CV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2023 RESULTS ON NOVEMBER 14, 2023

Rhea-AI Summary

CV Sciences, Inc. (OTCQB:CVSI) will release financial results for the third quarter ended September 30, 2023, before the stock market opens on Tuesday, November 14, 2023. The company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day. Investors interested in participating in the live call can also dial (877) 300-8521 from the U.S. or international callers can dial (412) 317-6026.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/05/2023 08:00 AM

News

CV Sciences, Inc. Launches Reserve Sleep Gummies

Rhea-AI Summary

CV Sciences launches +PlusCBD™ Reserve Collection Sleep Gummies to expand into the sleep aid market

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/14/2023 09:00 AM

News

CV Sciences, Inc. Reports Second Quarter 2023 Financial Results

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/01/2023 09:00 AM

News

CV SCIENCES, INC. TO ANNOUNCE SECOND QUARTER 2023 RESULTS ON AUGUST 14, 2023

Rhea-AI Summary

CV Sciences, Inc. will release financial results for Q2 2023 on August 14, 2023. A conference call with the investment community will be held on the same day. The webcast of the call will be available on the Company's website. A telephone replay will also be available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/01/2023 09:00 AM

News

CV Sciences to Participate in LD Micro Invitational Conference

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

05/15/2023 09:00 AM

News

CV Sciences, Inc. Reports First Quarter 2023 Financial Results

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of CV SCIENCES (CVSI)?

The current stock price of CV SCIENCES (CVSI) is $0.0353 as of December 23, 2024.

What is the market cap of CV SCIENCES (CVSI)?

The market cap of CV SCIENCES (CVSI) is approximately 7.4M.

What products does CV Sciences offer?

CV Sciences specializes in hemp extracts, softgels, and plant-based foods, providing consumers with science-backed, natural alternatives for health and wellness.

What are some recent innovations by CV Sciences?

CV Sciences recently launched +PlusCBD™ Pet wellness treats, including the Pet Hip and Joint Health Chews and Pet Calming Care Chews, designed to support pet well-being with premium CBD-infused formulations.

How does CV Sciences ensure product quality and safety?

CV Sciences conducts rigorous testing of its products through independent laboratories to ensure purity, potency, and compliance with industry standards, such as those set by the National Animal Supplement Council (NASC).

What strategic acquisitions has CV Sciences made recently?

CV Sciences recently acquired Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures, to enhance its production capabilities, drive operational efficiency, and expand its product offerings.

What is CV Sciences' approach to innovation and growth?

CV Sciences focuses on continuous innovation, strategic investments, and in-house manufacturing to drive growth, increase market share, and provide consumers with high-quality, research-supported products for holistic well-being.